Search Results
Your search for ,NOW matches 6737 pages
Showing 4001 - 4050FDA Approves Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed...
Expert Point of View: Manish Shah, MD and Daniel F. Hayes, MD, FACP, FASCO
Manish Shah, MD, Director of Gastrointestinal Oncology at NewYork-Presbyterian and Weill Cornell Medicine, was impressed with the findings of the two subanalyses of CALGB 89803. “The study found a 46% reduction in the risk of recurrence with two servings of tree nuts a week, and that’s more than ...
Tree Nut Consumption May Improve Outcomes in Stage III Colon Cancer
Tree nut consumption, as well as a generally healthy lifestyle, significantly reduced the risk of cancer recurrence and death in patients with stage III colon cancer treated in the Cancer and Leukemia Group B (CALGB) 89803 trial, researchers reported at the 2017 ASCO Annual Meeting. Two subanalyses ...
Making American Research Great Again
In the past 10 years, we have made remarkable advances in how we fight cancer. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens our own immune system to produce stunning results for many suffering from advanced cancer. Immunotherapy saved President Jimmy...
FDA Requests Removal of Oxymorphone Hydrochloride for Risks Related to Abuse
On June 8,the U.S. Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated oxymorphone hydrochloride (Opana ER), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the...
Value-Based Decision-Making Tools: The View Ahead
As new treatment decision-making tools make their way toward and into the clinic, oncologists are getting a sense of how they may affect clinical practice—and beginning to look farther down the road. “What do you see ahead for clinicians?” asked Christian Downs, JD, Executive Director of the...
ASCO 2017: Impact of Patient Age on Molecular Alterations in Colorectal Tumors
Younger patients with colon cancer appear to have more than three times as many mutations in their tumors as older patients, which could lead to more effective treatment decisions, according to researchers at Georgetown Lombardi Comprehensive Cancer Center. In a new study, they found that tumor...
ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...
Tumor Microvessel Density and Outcome With Bevacizumab in Ovarian Cancer
A retrospective biomarker analysis of the phase III GOG-0218 trial indicated a higher tumor microvessel density was associated with progression-free and overall survival benefit with bevacizumab (Avastin) vs placebo plus front-line chemotherapy in patients with ovarian cancer. These findings were...
ASCO 2017: BCMA-Specific CAR T-Cell Therapy Sends Relapsed/Refractory Multiple Myeloma Into Lasting Remission in an Early Trial
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving immunotherapy with chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein, or BCMA. Most patients had only mild side effects. The study was presented by Fan et al...
ASCO 2017: Web-Based System for Self-Reporting Symptoms Helps Patients Live Longer
A randomized clinical trial of 766 patients shows that a simple intervention—a Web-based tool that enables patients to report their symptoms in real time, triggering alerts to clinicians—can have major benefits, including longer survival. Patients with metastatic cancer who used the...
ASCO 2017: OlympiAD Trial: Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer
Findings from a phase III clinical trial of about 300 women may introduce poly ADP ribose polymerase (PARP) inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced,...
ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer...
ASCO 2017: Single-Dose Radiotherapy as Effective as Multiple Fractions in Relieving Symptoms of Spinal Cord Compression
Spinal cord compression is a common complication in people with metastatic cancer and is a major detriment to quality of life. Radiation treatment is widely used to relieve pain and other symptoms, but there is no standard recommended schedule, and approaches currently vary. Findings from a phase...
ASCO 2017: Low Testosterone Level After Testicular Cancer Is Common, Linked to Chronic Health Problems
In a large study, 38% of 491 testicular cancer survivors had low testosterone levels. Compared with survivors with normal testosterone levels, survivors with low testosterone levels were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile...
ASCO Announces CancerLinQ Partnerships With the FDA and the NCI
CancerLinQ®, ASCO’s big data initiative to rapidly improve the quality of cancer care, is partnering with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to study the real-world use of newly approved cancer treatments and speed and strengthen the...
Image-Guided Biopsies Accurately Identify Patients With Breast Cancer Who Achieve Pathologic Complete Response Following Neoadjuvant Therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response after neoadjuvant systemic therapy consisting of chemotherapy and/or targeted therapy. Should the...
After Nearly 4 Decades of Research, W.K. Alfred Yung, MD, Sees a New Era Ahead for Advances in Brain Tumors
After he was not accepted into the University of Hong Kong, plan B for W.K. Alfred Yung, MD, was to leave his country and immigrate to the United States to attend the University of Minnesota in Minneapolis—a move he considers more exile than choice. Born on April 8, 1948, in Hong Kong, Dr. Yung...
AACR Honors Mina J. Bissell, PhD, FAACR, With Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) recognized Mina J. Bissell, PhD, FAACR, with the 14th AACR Award for Lifetime Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR Award for Lifetime Achievement in Cancer Research was established in 2004 ...
For Eric P. Winer, MD, Empathy and a Sense of Purpose Lead to a Career in Oncology
Eric Paul Winer, MD, was born in Boston in 1956, a year when gasoline was 22 cents a gallon and IBM released the world’s first computer with a hard drive. His grandfather on his mother’s side had hemophilia and died 5 years before Dr. Winer was born. Although there was a 50% chance that Dr. Winer...
At the Forefront of Cancer Genetics, Bert Vogelstein, MD, Calls for Focus on Early Detection and Prevention
Bert Vogelstein, MD, was born on June 2, 1949, at The Johns Hopkins Hospital in Baltimore, Maryland, the same renowned institution where he would later make his mark in the field of cancer genetics. As a young teen, he was an enthusiast and independent consumer of books, one of which helped shape...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Special Awards and Lectures Presented During 2017 ASCO Annual Meeting
Recipients of ASCO’s Notable Awards and Lectures are individuals who have made extraordinary contributions to the research and treatment of patients with cancer. These individuals were honored during several special sessions held during ASCO’s 53rd Annual Meeting, where more than 30,000 physicians, ...
Pioneer in Geriatric Oncology, Hyman Muss, MD, Continues to Improve Care for Older Patients
Hyman Muss, MD, a pioneer in geriatric oncology, considers himself “a real Brooklyn boy.” His father was a dentist, and his uncle was a general practitioner. “They both practiced out of a small brownstone house in Brownsville-Crown Heights. It was sort of reminiscent of the famous movie The Last...
Distinguished Pediatric Oncologist Anna T. Meadows, MD, Led the Way for Studies in Childhood Cancer Survivors
Anna T. Meadows, MD, an internationally distinguished pediatric oncologist who led paradigm-changing survivorship research and clinical care of children with cancer, had an unusual introduction to the United States. “My mother was traveling abroad on vacation and got married in Poland. Although...
Waun Ki Hong, MD, FACP, Helped Change the Standard of Care in Laryngeal Cancer, Now Focuses on Chemoprevention and Precision Medicine
Waun Ki Hong, MD, FACP, one of the nation’s leading experts in head and neck and lung cancers, was born in South Korea and grew up in a tiny village outside the nation’s capital of Seoul. Number six of seven siblings, Dr. Hong described his early life in the cozy village as blissful, until the...
Clinical Researcher George P. Canellos, MD, Closely Involved With Two of the Most Influential Treatments in Cancer Care
George P. Canellos, MD, President of ASCO from 1993 to 1994, was born in Boston on November 1, 1934. “I came from a business family and never wanted to do business at all. As long back as I can remember, I always found medicine attractive—not only because you could help people, but you could also...
Nobel Laureate David Baltimore, PhD, Plays Integral Role in Linking Cell Biology and Cancer Genetics
David Baltimore, PhD, whose work profoundly influenced international science, was born on March 7, 1938, in Queens, New York, to Gertrude and Richard Baltimore. While he was in second grade, the family moved to Great Neck, New York, a middle-class suburb with top-notch public schools. “My father...
Renowned Hematologist Mojtaba Akhtari, MD, Reflects on a New Era in Treating Blood Cancers
The nationally recognized hematologist-oncologist Mojtaba Akhtari, MD, was born and reared in Tehran, Iran. “In my early years, I had a couple of cousins who were medical students. When I visited them in their homes, I was fascinated with the images in their medical text books. I would flip the...
ASCO and CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer
Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017. For patients with invasive breast...
ASCO President, Bruce E. Johnson, MD, FASCO, Participates in Key Research With EGFR Mutation in Lung Cancer
Bruce E. Johnson, MD, FASCO, 2017–2018 ASCO President, was born in St. Peter, Minnesota, and grew up on a rural dairy farm. “Neither of my parents had college degrees, but working on a dairy farm with them gave me a solid work ethic. I was working outside on the farm before I was 10 years old. In...
Precision Medicine and My Own Activism Are Keeping Me Alive
In 2009, I was living my dream. My work as a business development manager for a technology company was thriving; I had a satisfying social life; I was active in sports, especially hiking and biking; and I was involved in social justice causes as a volunteer at San Quentin State Prison, helping...
Former Vice President Joe Biden and Congressman Kevin Yoder Pledge Continued Support to Conquer Cancer
In a nearly hour-long address to more than 4,500 attendees at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) on April 3, former Vice President Joe Biden lambasted President Trump’s proposed $5.8 billion budget cut to the National Institutes of Health (NIH) and...
Weight Management and Physical Activity in Cancer Care: From Research to Real World
Is there enough evidence to support the incorporation of weight management and physical activity interventions into an oncology practice? And if so, what is the best way to do it? The answer to the first question was a resounding yes from oncologists, patient advocates, dietitians, public health...
Tackling the Obesity and Cancer Epidemic
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...
James Allison, PhD, Named One of TIME ’s 100 Most Influential People in 2017
The University of Texas MD Anderson Cancer Center Chair of Immunology, James Allison, PhD—whose pivotal insight to attack cancer by treating the immune system instead of the tumor revived cancer immunotherapy—has been named to the 2017 TIME 100 Most Influential People. His approach launched a...
Unique Challenges Facing Young Women With Breast Cancer
According to the American Cancer Society, over 252,700 new cases of invasive breast cancer will be diagnosed in 2017, and about 40,610 women will die of their disease. Between 7% and 10% of those new cases will be diagnosed in women younger than age 40, accounting for more than 40% of all cancer...
What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?
As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...
ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer
Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference.1 Previous research has suggested that radiotherapy may be of little help in this setting. The...
ASCO and Other Oncology, Medical Societies Speak Out Against White House’s Proposed Budget Cuts
On May 23, President Trump presented the White House’s fiscal year 2018 budget request, which proposes a $7.18 billion cut to the National Institutes of Health (NIH)—a budget decrease of 21%. In addition, it cuts the Center for Disease Control and Prevention’s chronic disease...
JNCCN 360, the Source for Tumor-Specific News and Treatment Updates, Available Now
Launched during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™, JNCCN360.org is the latest resource from the Journal of the National Comprehensive Cancer Network (JNCCN). Currently available for breast...
Common Causes of Death Predominate Among Long-Term Colorectal Cancer Survivors
Patients with colorectal cancer who survive at least 5 years are increasingly likely to die from causes that are common in the general population, highlighting the importance of screening and lifestyle modification, suggested a large cohort study conducted in California.1 The analysis of more than...
Marie Bleakley, MD, PhD, Receives Research Grant in Immuno-oncology From Stand Up To Cancer
Marie Bleakley, MD, PhD, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center (Fred Hutch), has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer (SU2C). Dr. Bleakley will use the 3-year, $750,000 award to develop T-cell therapies...
New Chief of CHOP’s Cellular Therapy and Transplant Section
A leading pediatric oncologist at Children’s Hospital of Philadelphia (CHOP), Stephan Grupp, MD, PhD, was named Chief of the Section of Cellular Therapy and Transplant in the Hospital’s Division of Oncology. Dr. Grupp, who has researched and led groundbreaking clinical trials of an innovative...
Metastatic Urothelial Carcinoma: A Model Malignancy for Immune Checkpoint Blockade
Platinum-based combination chemotherapy became a mainstay of first-line treatment for metastatic urothelial cancer in the 1980s. With combination platinum-based regimens, 40% to 50% of patients achieve an objective response to treatment. However, aside from approximately 5% to 10% of patients who...
The Ongoing Challenges of Lung Cancer Screening
Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy...
FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...
Expert Point of View: Julie Margenthaler, MD
“This study of 2,759 patients with ductal carcinoma in situ provides data for women who are considering their surgical options,” said Julie Margenthaler, MD, a breast surgeon at Washington University of Medicine, St. Louis, and Communications Chair of the American Society of Breast Surgeons...
First-in-Human Clinical Trial in Children and Young Adults With Leukemia
After phase I results of Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial, published by Gardner et al in Blood,1 showed T-cell immunotherapy to be effective in sending 93% of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial...
Short-Course Radiotherapy Plus Temozolomide Improves Survival in Older Patients With Glioblastoma
In a phase III trial reported in The New England Journal of Medicine, James R. Perry, MD, of Sunnybrook Health Sciences Centre, Toronto, and colleagues found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged at least 65 years with newly diagnosed...
